Refine by
Allergy Treatment Articles & Analysis
25 news found
What is Newborn Snoring? Oftentimes, newborns breathe noisily when they sleep. It may be caused due to extra mucus or dryness in their tiny nasal passages. However, if you notice your newborn baby actually snoring on a regular basis, consult with a doctor. If your snoring is causing issues with your partner or his/her snoring is irritating you at night, it is important that you seek timely ...
Its treatment principle is to transmit ultrasound waves deep into the skin to achieve deeper treatment results. ...
This means that while some trees are related and pollens are somewhat similar, many tree pollens have unique features that prevent the ability to create a single treatment for tree pollen allergy. For this reason, allergists test sensitized patients for multiple different tree pollens and subsequently treat each patient uniquely for their specific tree pollen ...
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. ...
Food Allergy Research and Education (FARE) has established that more than 32 million people in the US are victims of food allergy. Almost 8% of children with a food allergy are less than 5 years old and overall 4% of adults suffer from food allergies. ...
” The Company’s oral mucosal immunotherapy (OMIT) platform is based on the well-accepted principles of allergy immunotherapy. The company’s initial product, INT301, is an immunotherapy treatment for peanut allergy delivered via a specially-formulated toothpaste designed to optimize exposure of allergenic proteins to a ...
-GI Innovation-Medirama forms a ‘Joint Development Committee’ for professionalism maximization -Joint development for two new immuno-oncology… partial shared cooperative model of commercialization revenue GI Innovation, an innovative new drug development company signed a contract with Medirama, clinical development specialized company for joint research development of next ...
Angany’s first two therapeutic products will be used in the treatment of allergy to peanuts and human allergy to cats. The two companies will share a booth at the 2021 Annual Scientific Meeting of the American College of Asthma Allergy and Immunology (ACAAI) to be held from November 4th to 8th in New Orleans. ...
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the launch of its #PeanutAllergyStrong patient engagement campaign. ...
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. ...
In France, Angany’s R&D laboratory has managed to produce these monoclonal antibodies with a plant-based platform initially designed for the manufacturing of a new generation of vaccines against allergies. “The relevance of NAbs as preventive or therapeutic treatments is all about metrics: higher neutralization potency means lower effective doses ...
Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. The series B funding involved participation from top-tier investors and venture firms, including series A investors Khosla Ventures and Marc Benioff as well as new investors Seventure (Health for Life Capital ...
Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. ...
“During this global COVID-19 pandemic, many allergy patients are required to stay at home, reducing their ability to visit physicians’ offices for allergy treatments, such as allergy shots,” said Robert Pomrenke, CEO, Allovate. “Upon request, we are making free supplies of our Allerdent® product ...
Hans van Schijndel has a PhD in Biochemistry and is employed by HAL Allergy since 2012. In his career at HAL Allergy he served as Principal Scientist/Head of Pre-clinical Research and was engaged in several bio-technological projects including the Therapieallergene-Verordnung (TAV) program. In his position of Chief R&D Officer he will take care of this ...
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Siolta Therapeutics to its coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products. This new addition brings MTIG's membership to five companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products. Siolta ...
Allovate® retains the global rights to develop products based on the OMIT platform for the treatment of respiratory allergies. Allovate® has licensed the rights to develop the OMIT platform for the treatment of food allergies to Intrommune Therapeutics, which is initially focused on an FDA-approved ...
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company’s Ammonia ...
HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. ...
” In the near future, Aktivax will leverage the progress made under the BARDA contract to pursue consumer market emergency products such as severe allergy treatment, hypoglycemia, and opioid overdose. “Not surprisingly, the Government's need for robust, user-friendly auto-injectors with improved drug stability is similar to the needs of consumer ...